CommercialPrior AuthHigh impact
Calcitriol, Etelcalcetide, and Paricalcitol Injections (CPB 0022, reviewed 2026-02-11)
Aetna·Nephrology, Endocrinology, Internal Medicine·Pharmacy
Effective date
Feb 11, 2026
We identified it
Aug 12, 2026
Summary
Aetna has updated its coverage policy for three injectable medications used in chronic kidney disease management. Etelcalcetide (Parsabiv) now requires documented failure of at least 2 phosphate binders, 2 vitamin D analogs, and a 6-month trial of cinacalcet before approval. Calcitriol and paricalcitol remain covered for hypocalcemia/secondary hyperparathyroidism in hemodialysis patients, and all three drugs require precertification and specialist prescription (endocrinologist or nephrologist).
Action Required
By February 11, 2026: Billing and prior authorization teams must implement the following: (1) For all Parsabiv (etelcalcetide) requests, require documentation of therapeutic failure or contraindication/intolerance for: at least 2 phosphate binders (PhosLo, Fosrenol, Renvela, Renagel) with minimum 2-month trial each, AND at least 2 vitamin D analogs (calcitriol, Hectorol, Zemplar) with minimum 2-month trial each, AND at least 6-month trial of cinacalcet at maximum tolerated dose. (2) Update prior authorization system to mandate precertification contact (866-752-7021 or fax 888-267-3277) for all Parsabiv requests before claim submission. (3) Ensure all requests are routed to endocrinologists or nephrologists only; reject requests from other specialties. (4) For calcitriol and paricalcitol, confirm indication is limited to hypocalcemia and/or secondary hyperparathyroidism in chronic kidney disease patients on hemodialysis; all other indications are experimental/unproven and must be denied. (5) Add continuation-of-therapy review requirements: calcitriol/paricalcitol must show iPTH decrease or calcium/phosphorus improvement; Parsabiv must show iPTH decrease from baseline. (6) Communicate these changes to all contracted nephrology and endocrinology practices. Failure to comply will result in claim denials and potential provider compliance issues. Providers must use Statement of Medical Necessity (SMN) forms available through Specialty Pharmacy Precertification.